INTRODUCTION
The opening of a new medical research facility is, by definition, a tangible expression of progress, and a visible demonstration of continuing, firm dedication to medical science. In this particular instance, celebrating 75 years of pediatrics atYale, we are afforded a welcome opportunity to address a broad question raised often by those whose entire careers have been devoted to or are likely to be devoted to academic medicine.
The question -what is the world of medical science like for those based in the often frenetic, sometimes tumultuous pharmaceutical industry -can be answered in a number of ways. The "sound bite" answer is that it is a very different world, ferociously competitive -even dog eat dog (which of course contrasts so sharply with academia where it is just the opposite). Our less flippant response will focus on the nature and importance of bridges connecting two of the three key players in our country's medical research enterprise: academia and industry. The third key player is, of course, government in its many forms and functions.
COMPARING AND Closer examination of these two representative, leading edge academic and industrial institutions suggests research cultures that are distinct, complementary and, sometimes, convergent. We think there are five important dimensions which must be understood if alliances between these natural allies are to flourish:
The principal goals are critically different. For academia these are well known: the acquisition and dissemination of new information; the education of the next generation of medical researchers. Pharmaceutical research and development, on the other hand, has one overarching goal -the design, discovery, and development of new medicines. Acquiring proprietary rights through patents and licenses is a secondary, related goal. Further, dissemination of knowledge from basic as well as applied science is an important goal -in common with that of academia.
The organizational characters are distinct -as would be expected given the goals just described. The academic setting is noted for the independence and the autonomy of the individual investigator in initiating research efforts which are highly decentralized and usually quite discipline oriented. In industry research efforts and priorities are delineated, not by individual investigator preferences, but rather by a more centralized discovery and development program aimed at specific disease targets notable for unmet medical need and commercial opportunity.
The planning modes differ in important ways as well. In academia, research planning is a responsibility clearly delegated to the principal investigator and episodically tied to cycles of funding. In industry, planning is a continuous undertaking with responsibility for strategic program planning seated at the highest levels of the research organization and fed from its subunits with their therapeutic area emphasis. The industry planning process is continuous and inextricably linked to the budget process.
The funding for research programs is similarly distinct. In academia, the sources are invariably multiple -NIH, NSF, VA, HHMI, foundations, voluntary health agencies. In industry the source is invariably a single one, the business itself, reflecting the investment top management considers appropriate given the state of the business. In industry, research funding and business strategy are closely linked. In academia, success in securing funding defines the scope and scale of the efforts.
Not surprisingly, the principal interactions of academic and industrial medical research organizations with the federal government differ substantively. The academic organization has, for many decades, looked beseechingly to a variably responsive government for financial sponsorship of its work. In turn, it provides the expertise for the peer review process that effectively sets the research agenda in the institutions receiving funding. For the pharmaceutical company's research organization, relationships with the federal government are primarily and continuously linked to the regulatory oversight function of the FDA. Our personal experiences tell us that academia's relationship with NIH and other federal sponsors is more often characterized by advocacy, whereas FDA's relationship with the pharmaceutical industry is, by its very nature, legalistic and often adversarial. For completeness, it is important to point out industry's involvement with government through participation in cooperative research and development agreements and in the peer review process.
While the differences in the two research cultures are real -even formidable -considerable progress has occurred over the last two decades in recognizing their respective merits and building bridges. THE BRIDGE BETWEEN ACADEMIA AND INDUSTRY How are connections to be made between these institutions, so long separated by prejudice and misunderstanding as well as by fundamental purpose? To address this, we'll consider a metaphoric bridge with three structural elements: foundations; forms; and functions The characteristic forms of the bridge follow from the foundation "stones" just described. The most common, and some would say the most successful, form is represented by an industrial research contract with an individual academic investigator. These are aimed at focused acquisition of targets or technologies. Closely allied are the somewhat more broad-based agreements with one or a group of academic investigators aimed at a single therapeutic area. Quite straightforward arrangements govern industry's purchase of exclusive and non-exclusive technology licenses with varying royalty provisions and the traditional employment of academic consultants who serve on a retainer basis. Less frequent, and to date less successful in meeting the interdependent expectations and needs of the parties, have been the large "umbrella" agreements with an academic institution covering multiple investigators and/or targets. Historically general in scope, such agreements are often: less easily understood by the working scientists in the participating organizations; more difficult to oversee; and seen as too unrestricted to provide value to the industrial partner. (Zerit) . This medication is being widely used as part of the two and three drug combinations that are changing the outlook for patients with AIDS.
It took more than 15 years for YSM and BMS to build, travel, and maintain this bridge. It involved risk, uncertainty, debate, patience and trust. This particular bridge epitomizes the best in American medical research -creative basic science, effective technology transfer, committed industrial capability. More than a dream, successful academic/industrial cooperation may truly be the next critical frontier for our country's and the world's medical research enterprises.
CONCLUSION
As the Yale Children's Hospital Research Center opens, we see a strong parallel for it and the metaphoric bridge we have been discussing. The new Center is a jewel in Yale's crown; a site where intellectual strength and fine facilities meld to support one of academia's premier departments of Pediatrics. The Center will be a home for the discovery of fundamental knowledge which, hopefully will bridge, with industry's participation, to preventive, diagnostic or therapeutic modalities aimed toward improving the present and future health of our country's most precious resource -its children.
